Zachary Roberts - Jan 20, 2023 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
EVP of R&D
Signature
Veer Bhavnagri as attorney-in-fact
Stock symbol
ALLO
Transactions as of
Jan 20, 2023
Transactions value $
$0
Form type
4
Date filed
1/24/2023, 04:02 PM
Previous filing
Jan 9, 2023
Next filing
Mar 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Award $0 +252K $0.00 252K Jan 20, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to Buy) Award $0 +873K $0.00 873K Jan 20, 2023 Common Stock 873K $6.55 Direct F1

Explanation of Responses:

Id Content
F1 25% of the shares subject to the stock option shall vest on January 03, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.